Simon Ducharme, MD, MSc, FRCP(C)

Contact
simon.ducharme@mcgill.ca
6875 Boulevard LaSalle Montréal, QC H4H 1R3
ORCID iD: https://orcid.org/0000-0002-7309-1113
Chercheur, Centre de recherche Douglas
Professeur adjoint, Département de psychiatrie, Université McGill
Chercheur-boursier clinicien, Fonds de recherche du Québec – Santé (FRQS), Senior
Nom du laboratoire: Labo DFT et neuropsychiatrie
Groupe thématique: Vieillissement, cognition et maladie d'AlzheimerDivision: Recherche clinique
Le laboratoire FTD & Neuropsychiatry dirigé par le Dr Simon Ducharme vise à développer des outils cliniques et thérapeutiques pour les troubles neuropsychiatriques, en se concentrant sur les principaux troubles neurocognitifs. Nous menons des études translationnelles utilisant l’imagerie structurelle et fonctionnelle dans la démence frontotemporale (DFT) afin d’améliorer les marqueurs diagnostiques précoces de cette maladie dévastatrice. Notre groupe participe à plusieurs études nationales et internationales de neuro-imagerie sur la démence, ainsi qu’à des essais cliniques novateurs sur la maladie d’Alzheimer et la DFT.
Le Dr Simon Ducharme est titulaire d’un diplôme de médecine de l’Université de Montréal et d’une maîtrise de l’Université McGill. Il a effectué sa résidence en psychiatrie à McGill en 2012, et un fellowship en neurologie comportementale et neuropsychiatrie à l’Université Harvard en 2014.
Il est certifié en neurologie comportementale et neuropsychiatrie par le United Council for Neurological Subspecialties. Il travaille actuellement comme neuropsychiatre à l’Institut de santé mentale Douglas. Sa spécialité clinique est la démence frontotemporale.
Le Dr Ducharme a reçu plus de 35 prix d’excellence en enseignement ou en recherche, dont le Career Development Award 2013 de l’American Neuropsychiatric Association, et il est un clinicien-chercheur financé par le FRQS.
Ses recherches utilisent des techniques avancées d’imagerie cérébrale structurelle pour étudier les changements longitudinaux dans le développement du cerveau, de l’enfance à la vieillesse, et leur impact sur le comportement dans les domaines de la santé et de la psychopathologie. Ses projets actuels visent à développer de nouveaux biomarqueurs diagnostiques et pronostiques de neuro-imagerie pour la démence frontotemporale.
Il est le chercheur principal du site de Montréal pour l’étude Genetic Frontotemporal Dementia Initiative et le chef de l’équipe DFT du Consortium canadien sur la neurodégénérescence et le vieillissement. Il est l’actuel président du comité de recherche de l’American Neuropsychiatric Association. Le Dr Ducharme est responsable de plusieurs essais cliniques sur la maladie d’Alzheimer et les démences apparentées.
![]() | David Benrimoh, MD | Étudiant diplômé |
![]() | Tristin Best, MSc | Étudiant diplômé, programme IPN |
![]() | Simon Ducharme, MD, MSc, FRCP(C) | Chercheur principal |
![]() | Jake Levy, MD | Étudiant diplômé |
![]() | Ana Manera, MD | Chercheuse post-doctorale |
![]() | Jillian McCarthy, BSc | Étudiante diplômée |
![]() | Mahdie Soltaninejad | Étudiante diplômée, programme IPN |
![]() | Teodora Yaneva, MSc | Personnel de recherche |
Publications clés
Liste complète des publications.
- Manera AL, Dadar M, Collins DL, Ducharme S; Frontotemporal Lobar Degeneration Neuroimaging Initiative. Deformation based morphometry study of longitudinal MRI changes in behavioral variant frontotemporal dementia. Neuroimage Clin. 2019;24:102079. doi: 10.1016/j.nicl.2019.102079. Epub 2019 Nov 5. Pubmed PMID: 31795051.
- Ducharme S, Pearl-Dowler L, Gossink F, McCarthy J, Lai J, Dickerson BC, Chertkow H, Rapin L, Vijverberg E, Krudop W, Dols A, Pijnenburg Y. The Frontotemporal Dementia versus Primary Psychiatric Disorder (FTD versus PPD) Checklist: A Bedside Clinical Tool to Identify Behavioral Variant FTD in Patients with Late-Onset Behavioral Changes. J Alzheimers Dis. 2019;67(1):113-124. PubMed PMID: 30584146.
- Levy JP, Bocti C, Elie D, Paquet N, Soucy JP, Ducharme S. Bifrontal Hypermetabolism on Brain FDG-PET in a Case of C9orf72-Related Behavioral Variant of Frontotemporal Dementia. J Neuropsychiatry Clin Neurosci. 2019 Winter;31(1):92-94. PubMed PMID: 30404533.
- Benrimoh D, Pomerleau VJ, Demoustier A, Poulin S, Maltais JR, Brouillette J, Ducharme S. Why We Still Use “Organic Causes”: Results From a Survey of Psychiatrists and Residents. J Neuropsychiatry Clin Neurosci. 2019 Winter;31(1):57-64. PubMed PMID: 30305004.
- Alhusaini S, Karama S, Nguyen TV, Thiel A, Bernhardt BC, Cox SR, Corley J, Taylor A, Evans AC, Star JM, Bastin ME, Wardlaw JM, Deary IJ, Ducharme S. Association between carotid atheroma and cerebral cortex structure at age 73 years. Ann Neurol. 2018 Oct;84(4):576-587. PubMed PMID: 30179274.
- McCarthy J, Collins DL, Ducharme S. Morphometric MRI as a diagnostic biomarker of frontotemporal dementia: A systematic review to determine clinical applicability. Neuroimage Clin. 2018;20:685-696. PubMed PMID: 30218900.
- Ducharme S, Price BH, Dickerson BC. Apathy: a neurocircuitry model based on frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2018 Apr;89(4):389-396. PubMed PMID: 29066518.
- Ducharme S, Bajestan S, Dickerson BC, Voon V. Psychiatric Presentations of C9orf72 Mutation: What Are the Diagnostic Implications for Clinicians? J Neuropsychiatry Clin Neurosci. 2017 Summer;29(3):195-205. PubMed PMID: 28238272.
- Ducharme S, Albaugh MD, Nguyen TV, Hudziak JJ, Mateos-Pérez JM, Labbe A, Evans AC, Karama S. Trajectories of cortical thickness maturation in normal brain development–The importance of quality control procedures. Neuroimage. 2016 Jan 15;125:267-279. PubMed PMID: 26463175.
- Ducharme S, Murray ED, Seiner SJ, Tayeb H, Legesse B, Price BH. Retrospective Analysis of the Short-Term Safety of ECT in Patients With Neurological Comorbidities: A Guide for Pre-ECT Neurological Evaluations. J Neuropsychiatry Clin Neurosci. 2015 Fall;27(4):311-21. PubMed PMID: 25658682.
- Ducharme S, Price BH, Larvie M, Dougherty DD, Dickerson BC. Clinical Approach to the Differential Diagnosis Between Behavioral Variant Frontotemporal Dementia and Primary Psychiatric Disorders. Am J Psychiatry. 2015 Sep 1;172(9):827-37. PubMed PMID: 26324301.
- Ducharme S, Dickerson BC. The neuropsychiatric examination of the young-onset dementias. Psychiatr Clin North Am. 2015 Jun;38(2):249-64. PubMed PMID: 25998114.
- Karama S, Ducharme S, Corley J, Chouinard-Decorte F, Starr JM, Wardlaw JM, Bastin ME, Deary IJ. Cigarette smoking and thinning of the brain’s cortex. Mol Psychiatry. 2015 Jun;20(6):778-85. PubMed PMID: 25666755.
- Ducharme S, Albaugh MD, Hudziak JJ, Botteron KN, Nguyen TV, Truong C, Evans AC, Karama S. Anxious/depressed symptoms are linked to right ventromedial prefrontal cortical thickness maturation in healthy children and young adults. Cereb Cortex. 2014 Nov;24(11):2941-50. PubMed PMID: 23749874.
- Ducharme S, Guiot MC, Nikelski J, Chertkow H. Does a positive Pittsburgh Compound B scan in a patient with dementia equal Alzheimer disease?. JAMA Neurol. 2013 Jul;70(7):912-4. PubMed PMID: 23689280.
- Ducharme S, Hudziak JJ, Botteron KN, Albaugh MD, Nguyen TV, Karama S, Evans AC. Decreased regional cortical thickness and thinning rate are associated with inattention symptoms in healthy children. J Am Acad Child Adolesc Psychiatry. 2012 Jan;51(1):18-27 PubMed PMID: 22176936.
- Le Blanc G, Jetté Pomerleau V, McCarthy J, Borroni B, van Swieten J, Galimberti D, Sanchez-Valle R, LaForce R Jr, Moreno F, Synofzik M, Graff C, Masellis M, Tartaglia MC, Rowe JB, Vandenberghe R, Finger E, Tagliavini F, de Mendonça A, Santana I, Butler C, Gerhard A, Danek A, Levin J, Otto M, Frisoni G, Sorbi S, Rohrer JD, Ducharme S; Genetic Frontotemporal Dementia Initiative (GENFI). Faster Cortical Thinning and Surface Area Loss in Presymptomatic and Symptomatic C9orf72 Repeat Expansion Adult Carriers. Ann Neurol. 2020 Jul;88(1):113-122
- Ducharme S, Dols A, Laforce Jr R, Devenney E, Kumfor F, van den Stock J, Dallaire-Théroux C, Seelaar H, Gossink F, Vijverberg E, Huey E, Vandenbuicke M, Masellis M, Trieu C, Onyike C, Caramelli P, de Souza L, Santillo A, Landqvist Waldö M, Landin-Romero R, Piguet O, Kelso W, Eratne D, Velakouli D, Ikeda M, Perry D, Pressman P, Boeve B, Vandenberghe, R, Mendez M, Azuar C, Levy R, Le Ber I, Baez S, Lerner A, Ellajosyula R, Pasquier F, Galimberti D, Scarpini E, van Swieten J, Hornberger M, Rosen H, Hodges J, Diehl-Schmid J, Pijnenburg Y. Recommendations to Distinguish Behavioural Variant Frontotemporal Dementia from Psychiatric Disorders. Brain. 2020 Jun 1;143(6):1632-1650.
Publications
2025
Villeneuve, Sylvia; Poirier, Judes; Breitner, John C S; Tremblay-Mercier, Jennifer; Remz, Jordana; Raoult, Jean-Michel; Yakoub, Yara; Gallego-Rudolf, Jonathan; Qiu, Ting; Valdez, Alfonso Fajardo; Mohammediyan, Bery; Javanray, Mohammadali; Metz, Amelie; Sanami, Safa; Ourry, Valentin; Wearn, Alfie; Pastor-Bernier, Alexandre; Edde, Manon; Gonneaud, Julie; Strikwerda-Brown, Cherie; Tardif, Christine L; Gauthier, Claudine J; Descoteaux, Maxime; Dadar, Mahsa; Vachon-Presseau, Étienne; Baril, Andrée-Ann; Ducharme, Simon; Montembeault, Maxime; Geddes, Maiya R; Soucy, Jean-Paul; Rajah, Natasha; Laforce, Robert; Bocti, Christian; Davatzikos, Christos; Bellec, Lune; Rosa-Neto, Pedro; Baillet, Sylvain; Evans, Alan C; Collins, D Louis; Chakravarty, M Mallar; Blennow, Kaj; Zetterberg, Henrik; Spreng, R Nathan; and, Alexa Pichet Binette
The PREVENT-AD cohort: Accelerating Alzheimer's disease research and treatment in Canada and beyond Article de journal
Dans: Alzheimers Dement, vol. 21, no 10, p. e70653, 2025, ISSN: 1552-5279.
@article{pmid41020412,
title = {The PREVENT-AD cohort: Accelerating Alzheimer's disease research and treatment in Canada and beyond},
author = {Sylvia Villeneuve and Judes Poirier and John C S Breitner and Jennifer Tremblay-Mercier and Jordana Remz and Jean-Michel Raoult and Yara Yakoub and Jonathan Gallego-Rudolf and Ting Qiu and Alfonso Fajardo Valdez and Bery Mohammediyan and Mohammadali Javanray and Amelie Metz and Safa Sanami and Valentin Ourry and Alfie Wearn and Alexandre Pastor-Bernier and Manon Edde and Julie Gonneaud and Cherie Strikwerda-Brown and Christine L Tardif and Claudine J Gauthier and Maxime Descoteaux and Mahsa Dadar and Étienne Vachon-Presseau and Andrée-Ann Baril and Simon Ducharme and Maxime Montembeault and Maiya R Geddes and Jean-Paul Soucy and Natasha Rajah and Robert Laforce and Christian Bocti and Christos Davatzikos and Lune Bellec and Pedro Rosa-Neto and Sylvain Baillet and Alan C Evans and D Louis Collins and M Mallar Chakravarty and Kaj Blennow and Henrik Zetterberg and R Nathan Spreng and Alexa Pichet Binette and },
doi = {10.1002/alz.70653},
issn = {1552-5279},
year = {2025},
date = {2025-10-01},
journal = {Alzheimers Dement},
volume = {21},
number = {10},
pages = {e70653},
abstract = {The PResymptomatic EValuation of Experimental or Novel Treatments for Alzheimer's Disease (PREVENT-AD) is an investigator-driven study that was created in 2011 and enrolled cognitively normal older adults with a family history of sporadic AD. Participants are deeply phenotyped and have now been followed annually for more than 12 years (median follow-up 8.0 years, SD 3.1). Multimodal magnetic resonance imaging (MRI), genetic, neurosensory, clinical, cerebrospinal fluid, and cognitive data collected until 2017 on 348 participants who agreed to open sharing with the neuroscience community were already available. We now share a new release including 6 years of additional follow-up cognitive data, and additional MRI follow-ups, clinical progression, new longitudinal behavioral and lifestyle measures (questionnaires, actigraphy), longitudinal AD plasma biomarkers, amyloid-beta and tau positron emission tomography (PET), magnetoencephalography, as well as neuroimaging analytic measures from all MRI modalities. We describe the PREVENT-AD study, the data shared with the global research community, as well as the model we created to sustain longitudinal follow-ups while also allowing new innovative data collection. HIGHLIGHTS: The PResymptomatic EValuation of Experimental or Novel Treatments for Alzheimer's Disease (PREVENT-AD) is a single-site longitudinal study that started in 2011 with annual follow-up data collection on individuals at risk of Alzheimer's disease who were all cognitively normal at enrolment. All 387 participants were enrolled between 2011 and 2017 and 306 (79%) of these participants were still in the study as of December 2023. While the PREVENT-AD dataset was not originally planned to be shared with the global research community, 348 participants retrospectively consented for their data to be shared with researchers worldwide. The first release of data was in 2019. We now share a second release that includes 6 years of additional follow-up visits, information on clinical progression and novel cognitive, behavioral, genetic, plasma and neuroimaging (amyloid and tau positron emission tomography [PET], magnetoencephalography [MEG], and new magnetic resonance imaging [MRI] sequences) data. It also includes analytic outputs for neuroimaging modalities.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Rue, Ishana; Jones, Sherri Lee; de Boer, Sterre C M; Soltaninejad, Mahdie; Diehl-Schmid, Janine; Galimberti, Daniela; Arighi, Andrea; Halliday, Glenda; Landin-Romero, Ramon; Piguet, Olivier; Riedl, Lina; Pijnenburg, Yolande; Ducharme, Simon
Accuracy of FDG-PET brain scan to differentiate sporadic bvFTD of mild severity from late onset psychiatric disorders Article de journal
Dans: J Neurol, vol. 272, no 11, p. 727, 2025, ISSN: 1432-1459.
@article{pmid41136663,
title = {Accuracy of FDG-PET brain scan to differentiate sporadic bvFTD of mild severity from late onset psychiatric disorders},
author = {Ishana Rue and Sherri Lee Jones and Sterre C M de Boer and Mahdie Soltaninejad and Janine Diehl-Schmid and Daniela Galimberti and Andrea Arighi and Glenda Halliday and Ramon Landin-Romero and Olivier Piguet and Lina Riedl and Yolande Pijnenburg and Simon Ducharme},
doi = {10.1007/s00415-025-13467-5},
issn = {1432-1459},
year = {2025},
date = {2025-10-01},
journal = {J Neurol},
volume = {272},
number = {11},
pages = {727},
abstract = {BACKGROUND: Positron emission tomography with [F] fluorodeoxyglucose (FDG-PET) brain scan accurately differentiates behavioral variant frontotemporal dementia (bvFTD) from other neurodegenerative disorders. However, the accuracy of FDG-PET to differentiate bvFTD from primary psychiatric disorders (PPD) remains understudied, with prior studies reporting high false positive rates.nnMETHODS: Retrospective data from the DIagnostic and Prognostic Precision Algorithm for behavioral variant Frontotemporal Dementia (DIPPA-FTD) database included 508 sporadic bvFTD and 152 late-onset PPD cases (onset at age 45-75 years). 226 cases had an FDG-PET scan completed at baseline with a visual rating for bvFTD diagnosis (Yes, No, or Ambiguous). Follow-up clinical diagnosis at least 1 year later was used as the gold standard to calculate sensitivity and specificity of FDG-PET at baseline.nnRESULTS: Follow up consisted of 198 probable bvFTD cases (87.6%) and 28 PPD cases (12.4%). FDG-PET had a sensitivity of 87% and a specificity of 93% to identify bvFTD cases, with a diagnostic accuracy of 88%. Within the PPD group, 7.1% had false positives and 14.3% had ambiguous scans. Rates of false negatives (normal or ambiguous PET) in bvFTD were 13.1% and were 2.6 times more common in males.nnCONCLUSION: FDG-PET had excellent diagnostic accuracy to differentiate between sporadic bvFTD and late onset PPD, with a low true false positive rate in PPD. False negatives were more common in males with bvFTD. These results support the use of FDG-PET as an important step in the diagnostic algorithm for patients with late onset behavioral changes, although results can be misleading in some cases.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Liu, Ella; Jones, Sherri Lee; Light, Victoria; Teunissen, Charlotte; Bouzigues, Arabella; Russell, Lucy L; Foster, Phoebe H; Ferry-Bolder, Eve; van Swieten, John C; Jiskoot, Lize C; Seelaar, Harro; Sanchez-Valle, Raquel; Laforce, Robert; Graff, Caroline; Galimberti, Daniela; Vandenberghe, Rik; de Mendonça, Alexandre; Tiraboschi, Pietro; Santana, Isabel; Gerhard, Alexander; Levin, Johannes; Sorbi, Sandro; Otto, Markus; Butler, Chris R; Ber, Isabelle Le; Finger, Elizabeth; Tartaglia, Maria Carmela; Masellis, Mario; Rowe, James B; Synofzik, Matthis; Moreno, Fermin; Borroni, Barbara; Zetterberg, Henrik; Rohrer, Jonathan D; and, Simon Ducharme
Accuracy of blood-based neurofilament light to different genetic frontotemporal dementia from primary psychiatric disorders Article de journal
Dans: J Alzheimers Dis, p. 13872877251352103, 2025, ISSN: 1875-8908.
@article{pmid40605462,
title = {Accuracy of blood-based neurofilament light to different genetic frontotemporal dementia from primary psychiatric disorders},
author = {Ella Liu and Sherri Lee Jones and Victoria Light and Charlotte Teunissen and Arabella Bouzigues and Lucy L Russell and Phoebe H Foster and Eve Ferry-Bolder and John C van Swieten and Lize C Jiskoot and Harro Seelaar and Raquel Sanchez-Valle and Robert Laforce and Caroline Graff and Daniela Galimberti and Rik Vandenberghe and Alexandre de Mendonça and Pietro Tiraboschi and Isabel Santana and Alexander Gerhard and Johannes Levin and Sandro Sorbi and Markus Otto and Chris R Butler and Isabelle Le Ber and Elizabeth Finger and Maria Carmela Tartaglia and Mario Masellis and James B Rowe and Matthis Synofzik and Fermin Moreno and Barbara Borroni and Henrik Zetterberg and Jonathan D Rohrer and Simon Ducharme and },
doi = {10.1177/13872877251352103},
issn = {1875-8908},
year = {2025},
date = {2025-07-01},
journal = {J Alzheimers Dis},
pages = {13872877251352103},
abstract = {BackgroundGenetic frontotemporal dementia (FTD) along with Alzheimer's disease (AD), is one of the most prevalent early-onset dementias. The differential diagnosis of FTD from primary psychiatric disorder (PPD) has been challenging due to significant symptom overlap, particular as FTD often presents with prolonged psychiatric prodromes.ObjectiveThis study aims to evaluate whether blood-based neurofilament light chain (NfL) can differentiate genetic FTD from PPD, and to determine a global clinical cutoff to differentiate genetic FTD carriers from PPD with high specificity and sensitivity.MethodsData (ages 40-81) were obtained from FTD mutation carriers (GENFI; = 474; = 120 114 = 50 , = 190 controls), and PPD (Biobanque Signature; = 848). Blood-based NfL was measured with SIMOA HD-X (BbS) and SIMOA HD-1 (GENFI).ResultsBlood-based NfL was higher in all symptomatic mutations compared to PPD. Mildly symptomatic (0 < FTLD CDR-SOB-NM < 4) and carriers also had higher NfL. ROC curve revealed an optimal blood-based NfL cutoff of 22.1 pg/mL ( = 0.647) to distinguish symptomatic genetic FTD from PPD (78.5% sensitivity, 86.2% specificity, AUC = 0.908). For mildly symptomatic subjects, a cutoff of 16.2 pg/mL ( = 0.601) differentiated groups with 86.7% sensitivity and 73.5% specificity (AUC = 0.870).ConclusionsNfL holds potential as a blood-based biomarker for symptomatic genetic FTD carriers, with moderate accuracy to distinguish PPD from mild forms including .},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Planche, Vincent; Mansencal, Boris; Fonov, Vladimir; Manjon, José V; Tourdias, Thomas; Bouzigues, Arabella; Russell, Lucy L; Foster, Phoebe H; Ferry-Bolder, Eve; van Swieten, John C; Jiskoot, Lize C; Seelaar, Harro; Sanchez-Valle, Raquel; Laforce, Robert; Graff, Caroline; Galimberti, Daniela; Vandenberghe, Rik; de Mendonça, Alexandre; Tiraboschi, Pietro; Santana, Isabel; Gerhard, Alexander; Levin, Johannes; Sorbi, Sandro; Otto, Markus; Bertoux, Maxime; Lebouvier, Thibaud; Butler, Chris R; Ber, Isabelle Le; Finger, Elizabeth; Tartaglia, Maria Carmela; Masellis, Mario; Rowe, James B; Synofzik, Matthis; Moreno, Fermin; Borroni, Barbara; Rohrer, Jonathan D; Collins, D Louis; Ducharme, Simon; and, Pierrick Coupé
Anatomical progression of genetic frontotemporal lobar degeneration across the lifespan Article de journal
Dans: Brain, 2025, ISSN: 1460-2156.
@article{pmid40424598,
title = {Anatomical progression of genetic frontotemporal lobar degeneration across the lifespan},
author = {Vincent Planche and Boris Mansencal and Vladimir Fonov and José V Manjon and Thomas Tourdias and Arabella Bouzigues and Lucy L Russell and Phoebe H Foster and Eve Ferry-Bolder and John C van Swieten and Lize C Jiskoot and Harro Seelaar and Raquel Sanchez-Valle and Robert Laforce and Caroline Graff and Daniela Galimberti and Rik Vandenberghe and Alexandre de Mendonça and Pietro Tiraboschi and Isabel Santana and Alexander Gerhard and Johannes Levin and Sandro Sorbi and Markus Otto and Maxime Bertoux and Thibaud Lebouvier and Chris R Butler and Isabelle Le Ber and Elizabeth Finger and Maria Carmela Tartaglia and Mario Masellis and James B Rowe and Matthis Synofzik and Fermin Moreno and Barbara Borroni and Jonathan D Rohrer and D Louis Collins and Simon Ducharme and Pierrick Coupé and },
doi = {10.1093/brain/awaf195},
issn = {1460-2156},
year = {2025},
date = {2025-05-01},
journal = {Brain},
abstract = {The recent development of brain charts for the human lifespan offers an ideal modeling framework for pathologies such as genetic frontotemporal lobar degeneration (FTLD) which likely involve both neurodevelopmental and neurodegenerative processes over a lifetime. We have therefore combined this new methodological approach with MRI data from asymptomatic and symptomatic subjects, carrying C9orf72, MAPT or GRN mutations from the GENFI and ALLFTD cohorts. We analyzed 37,532 MRIs from control subjects covering the entire lifespan and a total of 1,341 MRIs from subjects with a pathogenic FTLD mutation, aged from 18 to 86 years old. We detected the first significant regional brain volume differences on average at 27 years old in C9orf72 and MAPT mutation carriers, and at 42 years old in GRN mutation carriers. The delay between the onset of anatomical changes and the average age of symptom onset (i.e. the presymptomatic phase) was 13 years for MAPT, 17 years for GRN, and 34 years for C9orf72 mutation carriers. In terms of effect size, cumulative atrophy over the lifespan was twice as severe in affected brain regions in MAPT than in GRN or C9orf72 mutation carriers. However, the neurodegenerative process was spatially more extensive in C9orf72 (35 brain regions affected out of the 61 tested) compared to GRN or MAPT mutations carriers (25 and 18 regions, respectively). Schematically, the chronological staging of atrophy progression showed an initial involvement of the thalamus in C9orf72 expansion carriers, followed by the fronto-temporo-insular regions, the striatum and the amygdala. In GRN mutation carriers, atrophy began in fronto-insular areas, before progressing toward subcortical structures. In MAPT mutation carriers, atrophy affected the anterior temporal pole with the amygdala and hippocampus, before progressing to fronto-insular regions and the striatum. Our results using brain charts for the human lifespan show that C9orf72 is the most diffuse but also the slowest to emerge among genetic FTLD. MAPT FTLD is more aggressive and focal, while GRN FTLD is also rapidly progressive but with a later onset of the presymptomatic phase. Beyond quantification of the anatomical progression of genetic FTLD over the lifespan, these results may help determine the best timing to model and test disease-modifying strategies in FTLD, and monitor their effect in future clinical trials.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Mukwikwi, Elvis-Raymond; Jones, Sherri Lee; Manera, Ana L; Salpeter, Rebecca; Fumagalli, Giorgio Giulio; Eratne, Dhamidhu; Kang, Matthew J Y; Bertoux, Maxime; Didic, Mira; Katisko, Kasper; Solje, Eino; Santillo, Alexander F; Laforce, Robert Jr; Schroeter, Matthias L; den Stock, Jan Van; Vandenbulcke, Mathieu; Morin, Alexandre; de Boer, Sterre; Pijnenburg, Yolande; and, Simon Ducharme
Prevalence and Features of Misdiagnosis of Primary Psychiatric Disorders Among bvFTD Patients Article de journal
Dans: J Neuropsychiatry Clin Neurosci, p. appineuropsych20240238, 2025, ISSN: 1545-7222.
@article{pmid40289591,
title = {Prevalence and Features of Misdiagnosis of Primary Psychiatric Disorders Among bvFTD Patients},
author = {Elvis-Raymond Mukwikwi and Sherri Lee Jones and Ana L Manera and Rebecca Salpeter and Giorgio Giulio Fumagalli and Dhamidhu Eratne and Matthew J Y Kang and Maxime Bertoux and Mira Didic and Kasper Katisko and Eino Solje and Alexander F Santillo and Robert Jr Laforce and Matthias L Schroeter and Jan Van den Stock and Mathieu Vandenbulcke and Alexandre Morin and Sterre de Boer and Yolande Pijnenburg and Simon Ducharme and },
doi = {10.1176/appi.neuropsych.20240238},
issn = {1545-7222},
year = {2025},
date = {2025-04-01},
journal = {J Neuropsychiatry Clin Neurosci},
pages = {appineuropsych20240238},
abstract = {OBJECTIVE: Previous studies have reported misdiagnosis rates of nondegenerative primary psychiatric disorders of up to 50% among patients with behavioral variant frontotemporal dementia (bvFTD). The authors hypothesized that misdiagnosis rates have decreased over time because of an increased awareness and a better understanding of psychiatric prodromes of FTD.nnMETHODS: Retrospective data on past psychiatric trajectories of individuals with probable or definite bvFTD (N=609) were acquired from 12 sites of the Neuropsychiatric International Consortium on FTD. Symptom profiles, primary psychiatric disorder diagnoses, and treatment information were collected from medical records. The authors used descriptive statistics to characterize past diagnostic trajectories, chi-square and t tests to compare groups, and logistic regressions to determine risk factors for diagnostic errors.nnRESULTS: Of 609 bvFTD patients, 33% received a primary psychiatric disorder diagnosis after the onset of bvFTD symptoms but before a formal bvFTD diagnosis. In 13% (N=80) of all bvFTD cases, the diagnosis was retrospectively considered erroneous. The most common misdiagnosis was major depressive disorder, followed by anxiety disorders and psychosis. The remaining cases were classified as psychiatric prodromes (N=68) and comorbid conditions (N=42). Patients with misdiagnoses were significantly younger, by about 5.5 years, than those without such diagnoses and had higher rates of depressed mood, dietary changes, stereotypy, somatization, and anxiety symptoms. Only younger age predicted erroneous diagnoses.nnCONCLUSIONS: The rate of patients who were misdiagnosed as having primary psychiatric disorders was much lower than in previous reports, suggesting improvements in the quality of diagnostic assessments. Misdiagnoses were more common among younger patients, with some psychiatric symptoms being overrepresented in such cases.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Mirza, Saira S; Pasternak, Maurice; Paterson, Andrew D; Rogaeva, Ekaterina; Tartaglia, Maria C; Mitchell, Sara B; Black, Sandra E; Freedman, Morris; Tang-Wai, David; Bouzigues, Arabella; Russell, Lucy L; Foster, Phoebe H; Ferry-Bolder, Eve; Bocchetta, Martina; Cash, David M; Zetterberg, Henrik; Sogorb-Esteve, Aitana; van Swieten, John; Jiskoot, Lize C; Seelaar, Harro; Sanchez-Valle, Raquel; Laforce, Robert; Graff, Caroline; Galimberti, Daniela; Vandenberghe, Rik; de Mendonça, Alexandre; Tiraboschi, Pietro; Santana, Isabel; Gerhard, Alexander; Levin, Johannes; Sorbi, Sandro; Otto, Markus; Pasquier, Florence; Ducharme, Simon; Butler, Chris; Ber, Isabelle Le; Finger, Elizabeth; Rowe, James B; Synofzik, Matthis; Moreno, Fermin; Borroni, Barbara; Rohrer, Jonathan D; and, Mario Masellis
Disease-modifying effects of TMEM106B in genetic frontotemporal dementia: a longitudinal GENFI study Article de journal
Dans: Brain, 2025, ISSN: 1460-2156.
@article{pmid40260680,
title = {Disease-modifying effects of TMEM106B in genetic frontotemporal dementia: a longitudinal GENFI study},
author = {Saira S Mirza and Maurice Pasternak and Andrew D Paterson and Ekaterina Rogaeva and Maria C Tartaglia and Sara B Mitchell and Sandra E Black and Morris Freedman and David Tang-Wai and Arabella Bouzigues and Lucy L Russell and Phoebe H Foster and Eve Ferry-Bolder and Martina Bocchetta and David M Cash and Henrik Zetterberg and Aitana Sogorb-Esteve and John van Swieten and Lize C Jiskoot and Harro Seelaar and Raquel Sanchez-Valle and Robert Laforce and Caroline Graff and Daniela Galimberti and Rik Vandenberghe and Alexandre de Mendonça and Pietro Tiraboschi and Isabel Santana and Alexander Gerhard and Johannes Levin and Sandro Sorbi and Markus Otto and Florence Pasquier and Simon Ducharme and Chris Butler and Isabelle Le Ber and Elizabeth Finger and James B Rowe and Matthis Synofzik and Fermin Moreno and Barbara Borroni and Jonathan D Rohrer and Mario Masellis and },
doi = {10.1093/brain/awaf019},
issn = {1460-2156},
year = {2025},
date = {2025-04-01},
journal = {Brain},
abstract = {Common variants within TMEM106B are associated with risk for frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP). The G allele of the top single nucleotide polymorphism, rs1990622, confers protection against FTLD-TDP, including genetic cases due to GRN mutations or C9orf72 hexanucleotide repeat expansions. However, the effects of interaction between TMEM106B-rs1990622 and frontotemporal dementia (FTD) mutations on disease endophenotypes in genetic FTD are unknown. This longitudinal cohort study was embedded within the GENetic Frontotemporal dementia Initiative (GENFI). We included 518 participants from 222 families [209 non-carriers; 222 presymptomatic carriers (C9orf72 = 79; GRN = 101, MAPT = 42); 87 symptomatic carriers (C9orf72 = 45; GRN = 29; MAPT = 13)] followed for up to 7 years. Using linear mixed-effects models, we examined the effects of a triple interaction between TMEM106B-rs1990622G allele dosage (additive model: 0, 1 or 2 alleles) and autosomal dominant FTD mutations with clinical status, and time from baseline on (i) grey matter volume using a voxel-based analysis; (ii) serum neurofilament light chain (NfL) levels; and (iii) cognitive and behavioural measures. Mean age of participants was 47.9 ± 13.8 years, 58.1% were female and 61% had at least one G allele. C9orf72: rs1990622G allele dosage was associated with less atrophy within the right occipital region in presymptomatic carriers at baseline, and reduced atrophy rate within putamen and caudate nucleus, right frontotemporal regions, left cingulate and bilateral insular cortices in symptomatic carriers over time; lower NfL levels in presymptomatic carriers at baseline; better executive functions and language abilities in presymptomatic carriers; and maintained overall cognitive functions and behaviour in symptomatic carriers over time. GRN: rs1990622G allele dosage was associated with reduced grey matter atrophy rate within the right temporal and occipital regions in presymptomatic carriers, and within the right frontal cortex and insula over time in symptomatic carriers; lower serum NfL levels over time in presymptomatic carriers and lower NfL levels at both baseline and over time in symptomatic carriers; and better global cognitive performance at baseline and higher attention/processing speed scores over time in symptomatic carriers. MAPT: rs1990622G allele dosage was associated with reduced grey matter atrophy rate within the right inferior frontal gyrus in symptomatic carriers, but no effects on serum NfL or cognitive/behavioural measures. TMEM106B-rs1990622G allele dosage showed protective effects on multiple endophenotypes predominantly in GRN and C9orf72 groups. Therefore, TMEM106B genotype should be assessed in clinical trials, particularly of GRN- and C9orf72-related genetic FTD, due to its modifying effects on biomarker, imaging, cognitive and clinical outcomes.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Liu, Xulin; de Boer, Sterre C M; Cortez, Kasey; Poos, Jackie M; Illán-Gala, Ignacio; Heuer, Hilary; Forsberg, Leah K; Casaletto, Kaitlin; Memel, Molly; Appleby, Brian S; Barmada, Sami; Bozoki, Andrea; Clark, David; Cobigo, Yann; Darby, Ryan; Dickerson, Bradford C; Domoto-Reilly, Kimiko; Galasko, Douglas R; Geschwind, Daniel H; Ghoshal, Nupur; Graff-Radford, Neill R; Grant, Ian M; Hsiung, Ging-Yuek Robin; Honig, Lawrence S; Huey, Edward D; Irwin, David; Kantarci, Kejal; Léger, Gabriel C; Litvan, Irene; Mackenzie, Ian R; Masdeu, Joseph C; Mendez, Mario F; Onyike, Chiadi U; Pascual, Belen; Pressman, Peter; Bayram, Ece; Ramos, Eliana Marisa; Roberson, Erik D; Rogalski, Emily; Bouzigues, Arabella; Russell, Lucy L; Foster, Phoebe H; Ferry-Bolder, Eve; Masellis, Mario; van Swieten, John; Jiskoot, Lize; Seelaar, Harro; Sanchez-Valle, Raquel; Laforce, Robert; Graff, Caroline; Galimberti, Daniela; Vandenberghe, Rik; de Mendonça, Alexandre; Tiraboschi, Pietro; Santana, Isabel; Gerhard, Alexander; Levin, Johannes; Sorbi, Sandro; Otto, Markus; Pasquier, Florence; Ducharme, Simon; Butler, Chris R; Ber, Isabelle Le; Finger, Elizabeth; Rowe, James B; Synofzik, Matthis; Moreno, Fermin; Borroni, Barbara; Boeve, Brad F; Boxer, Adam L; Rosen, Howie J; Pijnenburg, Yolande A L; Rohrer, Jonathan D; and, Maria Carmela Tartaglia
Sex differences in clinical phenotypes of behavioral variant frontotemporal dementia Article de journal
Dans: Alzheimers Dement, vol. 21, no 4, p. e14608, 2025, ISSN: 1552-5279.
@article{pmid40277074,
title = {Sex differences in clinical phenotypes of behavioral variant frontotemporal dementia},
author = {Xulin Liu and Sterre C M de Boer and Kasey Cortez and Jackie M Poos and Ignacio Illán-Gala and Hilary Heuer and Leah K Forsberg and Kaitlin Casaletto and Molly Memel and Brian S Appleby and Sami Barmada and Andrea Bozoki and David Clark and Yann Cobigo and Ryan Darby and Bradford C Dickerson and Kimiko Domoto-Reilly and Douglas R Galasko and Daniel H Geschwind and Nupur Ghoshal and Neill R Graff-Radford and Ian M Grant and Ging-Yuek Robin Hsiung and Lawrence S Honig and Edward D Huey and David Irwin and Kejal Kantarci and Gabriel C Léger and Irene Litvan and Ian R Mackenzie and Joseph C Masdeu and Mario F Mendez and Chiadi U Onyike and Belen Pascual and Peter Pressman and Ece Bayram and Eliana Marisa Ramos and Erik D Roberson and Emily Rogalski and Arabella Bouzigues and Lucy L Russell and Phoebe H Foster and Eve Ferry-Bolder and Mario Masellis and John van Swieten and Lize Jiskoot and Harro Seelaar and Raquel Sanchez-Valle and Robert Laforce and Caroline Graff and Daniela Galimberti and Rik Vandenberghe and Alexandre de Mendonça and Pietro Tiraboschi and Isabel Santana and Alexander Gerhard and Johannes Levin and Sandro Sorbi and Markus Otto and Florence Pasquier and Simon Ducharme and Chris R Butler and Isabelle Le Ber and Elizabeth Finger and James B Rowe and Matthis Synofzik and Fermin Moreno and Barbara Borroni and Brad F Boeve and Adam L Boxer and Howie J Rosen and Yolande A L Pijnenburg and Jonathan D Rohrer and Maria Carmela Tartaglia and },
doi = {10.1002/alz.14608},
issn = {1552-5279},
year = {2025},
date = {2025-04-01},
journal = {Alzheimers Dement},
volume = {21},
number = {4},
pages = {e14608},
abstract = {INTRODUCTION: Higher male prevalence in sporadic behavioral variant frontotemporal dementia (bvFTD) has been reported. We hypothesized differences in phenotypes between genetic and sporadic bvFTD females resulting in underdiagnosis of sporadic bvFTD females.nnMETHODS: We included genetic and sporadic bvFTD patients from two multicenter cohorts. We compared behavioral and cognitive symptoms, and gray matter volumes, between genetic and sporadic cases in each sex.nnRESULTS: Females with sporadic bvFTD showed worse compulsive behavior (p = 0.026) and language impairments (p = 0.024) compared to females with genetic bvFTD (n = 152). Genetic bvFTD females had smaller gray matter volumes than sporadic bvFTD females, particularly in the parietal lobe.nnDISCUSSION: Females with sporadic bvFTD exhibit a distinct clinical phenotype compared to females with genetic bvFTD. This difference may explain the discrepancy in prevalence between genetic and sporadic cases, as some females without genetic mutations may be misdiagnosed due to atypical bvFTD symptom presentation.nnHIGHLIGHTS: Sex ratio is equal in genetic behavioral variant of frontotemporal dementia (bvFTD), whereas more males are present in sporadic bvFTD. Distinct neuropsychiatric phenotypes exist between sporadic and genetic bvFTD in females. Phenotype might explain the sex ratio difference between sporadic and genetic cases.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Nevler, Naomi; Niehoff, Debra; Gleixner, Amanda M; Dodge, Shana; Vogel, Adam P; Hill, Derek L; Ducharme, Simon; Staffaroni, Adam M; Yunusova, Yana; Au, Rhoda; Macwhinney, Brian; Wong, Bonnie; Parish-Morris, Julia; Geronimo, Andrew; Hansen, Bryan J; Beattie, Zachary T; Stephenson, Diane T; Boxer, Adam L; Dacks, Penny; Rohrer, Jonathan D
Developing digital health technologies for frontotemporal degeneration Article de journal
Dans: Alzheimers Dement, vol. 21, no 4, p. e70082, 2025, ISSN: 1552-5279.
@article{pmid40285380,
title = {Developing digital health technologies for frontotemporal degeneration},
author = {Naomi Nevler and Debra Niehoff and Amanda M Gleixner and Shana Dodge and Adam P Vogel and Derek L Hill and Simon Ducharme and Adam M Staffaroni and Yana Yunusova and Rhoda Au and Brian Macwhinney and Bonnie Wong and Julia Parish-Morris and Andrew Geronimo and Bryan J Hansen and Zachary T Beattie and Diane T Stephenson and Adam L Boxer and Penny Dacks and Jonathan D Rohrer},
doi = {10.1002/alz.70082},
issn = {1552-5279},
year = {2025},
date = {2025-04-01},
journal = {Alzheimers Dement},
volume = {21},
number = {4},
pages = {e70082},
abstract = {Frontotemporal degeneration (FTD) is a rare neurodegenerative disease in which patients can present with cognitive, behavioral, motor, and speech impairment. Currently, there are no approved therapies available to slow or halt disease progression. Detection and monitoring of patient symptoms is challenging for this heterogeneous disease and has negatively impacted progress in FTD clinical trials. Rapid technological advancements can promote the development of digital health technologies (DHTs) capable of capturing even the most subtle clinical impairments. DHTs are computing platforms being designed to measure meaningful aspects of disease onset and progression. Here we present some of the numerous tools currently being developed to measure changes in the functional domains that become impaired in FTD, challenges faced by developers, and a proposed roadmap for developing fit-for-purpose DHTs that will aid in the development of effective therapies for FTD. HIGHLIGHTS: DHTs are being developed to assess FTD onset and progression. Tool developers must overcome numerous challenges in creating effective applications. Guidance to tool developers aims to benefit FTD drug development and patient care.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Smith, Eric E; Phillips, Natalie A; Feldman, Howard H; Borrie, Michael; Ganesh, Aravind; Henri-Bhargava, Alexandre; Desmarais, Philippe; Frank, Andrew; Badhwar, AmanPreet; Barlow, Laura; Bartha, Robert; Best, Sarah; Bethell, Jennifer; Bhangu, Jaspreet; Black, Sandra E; Bocti, Christian; Bronskill, Susan E; Burhan, Amer M; Calon, Frederic; Camicioli, Richard; Campbell, Barry; Collins, D Louis; Dadar, Mahsa; DeMarco, Mari L; Ducharme, Simon; Duchesne, Simon; Einstein, Gillian; Fisk, John D; Gawryluk, Jodie R; Grossman, Linda; Ismail, Zahinoor; Itzhak, Inbal; Joshi, Manish; Harrison, Arthur; Kröger, Edeltraut; Kumar, Sanjeev; Laforce, Robert; Lanctot, Krista L; Lau, Meghan; Lee, Linda; Masellis, Mario; Massoud, Fadi; Mitchell, Sara B; Montero-Odasso, Manuel; Barnett, Karen Myers; Nygaard, Haakon B; Pasternak, Stephen H; Peters, Jody; Rajah, M Natasha; Robillard, Julie M; Rockwood, Ken; Rosa-Neto, Pedro; Seitz, Dallas P; Soucy, Jean-Paul; Trenaman, Shanna C; Wellington, Cheryl L; Zadem, Aicha; and, Howard Chertkow
Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future research Article de journal
Dans: J Prev Alzheimers Dis, vol. 12, no 3, p. 100068, 2025, ISSN: 2426-0266.
@article{pmid39893139,
title = {Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future research},
author = {Eric E Smith and Natalie A Phillips and Howard H Feldman and Michael Borrie and Aravind Ganesh and Alexandre Henri-Bhargava and Philippe Desmarais and Andrew Frank and AmanPreet Badhwar and Laura Barlow and Robert Bartha and Sarah Best and Jennifer Bethell and Jaspreet Bhangu and Sandra E Black and Christian Bocti and Susan E Bronskill and Amer M Burhan and Frederic Calon and Richard Camicioli and Barry Campbell and D Louis Collins and Mahsa Dadar and Mari L DeMarco and Simon Ducharme and Simon Duchesne and Gillian Einstein and John D Fisk and Jodie R Gawryluk and Linda Grossman and Zahinoor Ismail and Inbal Itzhak and Manish Joshi and Arthur Harrison and Edeltraut Kröger and Sanjeev Kumar and Robert Laforce and Krista L Lanctot and Meghan Lau and Linda Lee and Mario Masellis and Fadi Massoud and Sara B Mitchell and Manuel Montero-Odasso and Karen Myers Barnett and Haakon B Nygaard and Stephen H Pasternak and Jody Peters and M Natasha Rajah and Julie M Robillard and Ken Rockwood and Pedro Rosa-Neto and Dallas P Seitz and Jean-Paul Soucy and Shanna C Trenaman and Cheryl L Wellington and Aicha Zadem and Howard Chertkow and },
doi = {10.1016/j.tjpad.2025.100068},
issn = {2426-0266},
year = {2025},
date = {2025-03-01},
journal = {J Prev Alzheimers Dis},
volume = {12},
number = {3},
pages = {100068},
abstract = {Lecanemab and donanemab are monoclonal antibody therapies that remove amyloid-beta from the brain. They are the first therapies that alter a fundamental mechanism, amyloid-beta deposition, in Alzheimer disease (AD). To inform Canadian decisions on approval and use of these drugs, the Canadian Consortium on Neurodegeneration in Aging commissioned Work Groups to review evidence on the efficacy and safety of these new therapies, as well as their projected impacts on Canadian dementia systems of care. We included persons with lived experience with Alzheimer disease in the discussion about the benefits and harms. Our review of the trial publications found high quality evidence of statistically significant group differences, but also recognized that there are mixed views on the clinical relevance of the observed differences and the value of therapy for individual patients. The drugs are intended for persons with early AD, at a stage of mild cognitive impairment or mild dementia. If patients are treated, then confirmation of AD by positron emission tomography or cerebrospinal fluid analysis and monitoring for risk of amyloid-related imaging abnormalities was recommended, as done in the clinical trials, although it would strain Canadian resource capacity. More data are needed to determine the size of the potentially eligible treatment population in Canada.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Yakoub, Yara; Gonzalez-Ortiz, Fernando; Ashton, Nicholas J; Déry, Christine; Strikwerda-Brown, Cherie; St-Onge, Frédéric; Ourry, Valentin; Schöll, Michael; Geddes, Maiya R; Ducharme, Simon; Montembeault, Maxime; Rosa-Neto, Pedro; Soucy, Jean-Paul; Breitner, John C S; Zetterberg, Henrik; Blennow, Kaj; Poirier, Judes; and, Sylvia Villeneuve
Plasma p-tau217 identifies cognitively normal older adults who will develop cognitive impairment in a 10-year window Article de journal
Dans: Alzheimers Dement, vol. 21, no 2, p. e14537, 2025, ISSN: 1552-5279.
@article{pmid40008832,
title = {Plasma p-tau217 identifies cognitively normal older adults who will develop cognitive impairment in a 10-year window},
author = {Yara Yakoub and Fernando Gonzalez-Ortiz and Nicholas J Ashton and Christine Déry and Cherie Strikwerda-Brown and Frédéric St-Onge and Valentin Ourry and Michael Schöll and Maiya R Geddes and Simon Ducharme and Maxime Montembeault and Pedro Rosa-Neto and Jean-Paul Soucy and John C S Breitner and Henrik Zetterberg and Kaj Blennow and Judes Poirier and Sylvia Villeneuve and },
doi = {10.1002/alz.14537},
issn = {1552-5279},
year = {2025},
date = {2025-02-01},
journal = {Alzheimers Dement},
volume = {21},
number = {2},
pages = {e14537},
abstract = {INTRODUCTION: We assessed the prognostic accuracy of plasma p-tau217 in predicting the progression to mild cognitive impairment (MCI) in cognitively unimpaired (CU) individuals over a mean follow-up of 5.65 years after plasma collection (range 1.01-10.47).nnMETHODS: We included 215 participants from the PREVENT-AD cohort with plasma Aβ and p-tau217, 159 with cerebrospinal fluid (CSF) Aβ and p-tau217, and 155 with F-NAV4694 and F-flortaucipir PET scans. MCI progression was determined by multidisciplinary consensus among memory experts blind to biomarker and genetic information.nnRESULTS: Cox proportional hazard models indicated a greater progression rate in A+T+ and A-T+ compared to A-T- individuals (HR = 7.81 [95% CI = 3.92 to 15.59] and HR = 4.25 [1.60-11.31] respectively). Similar results were found with CSF (HR = 3.63 [1.72-7.70]) and PET (HR = 9.30 [3.67-23.55]).nnDISCUSSION: Plasma p-tau217 is a prognostic marker for identifying individuals who will develop cognitive impairment within ten years.nnHIGHLIGHTS: Elevated plasma p-tau217 levels in CU individuals indicate future clinical progression. Adding plasma Aβ status to p-tau markers did not improve the prediction to MCI. All individuals with abnormal tau PET measured in a temporal meta-ROI progressed to MCI.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Soskic, Sonja; Tregidgo, Henry F J; Todd, Emily G; Bouzigues, Arabella; Cash, David M; Russell, Lucy L; Thomas, David L; Malone, Ian B; Foster, Phoebe H; Ferry-Bolder, Eve; van Swieten, John C; Jiskoot, Lize C; Seelaar, Harro; Sanchez-Valle, Raquel; Laforce, Robert; Graff, Caroline; Galimberti, Daniela; Vandenberghe, Rik; de Mendonça, Alexandre; Tiraboschi, Pietro; Santana, Isabel; Gerhard, Alexander; Levin, Johannes; Nacmias, Benedetta; Otto, Markus; Bertoux, Maxime; Lebouvier, Thibaud; Ducharme, Simon; Butler, Christopher R; Ber, Isabelle Le; Finger, Elizabeth C; Tartaglia, Maria Carmela; Masellis, Mario; Rowe, James B; Synofzik, Matthis; Moreno, Fermin; Borroni, Barbara; Alexander, Daniel C; Iglesias, Juan Eugenio; Rohrer, Jonathan D; and, Martina Bocchetta
Thalamus involvement in genetic frontotemporal dementia assessed using structural and diffusion MRI: a GENFI study Article de journal
Dans: Brain Commun, vol. 7, no 6, p. fcaf420, 2025, ISSN: 2632-1297.
@article{pmid41245435,
title = {Thalamus involvement in genetic frontotemporal dementia assessed using structural and diffusion MRI: a GENFI study},
author = {Sonja Soskic and Henry F J Tregidgo and Emily G Todd and Arabella Bouzigues and David M Cash and Lucy L Russell and David L Thomas and Ian B Malone and Phoebe H Foster and Eve Ferry-Bolder and John C van Swieten and Lize C Jiskoot and Harro Seelaar and Raquel Sanchez-Valle and Robert Laforce and Caroline Graff and Daniela Galimberti and Rik Vandenberghe and Alexandre de Mendonça and Pietro Tiraboschi and Isabel Santana and Alexander Gerhard and Johannes Levin and Benedetta Nacmias and Markus Otto and Maxime Bertoux and Thibaud Lebouvier and Simon Ducharme and Christopher R Butler and Isabelle Le Ber and Elizabeth C Finger and Maria Carmela Tartaglia and Mario Masellis and James B Rowe and Matthis Synofzik and Fermin Moreno and Barbara Borroni and Daniel C Alexander and Juan Eugenio Iglesias and Jonathan D Rohrer and Martina Bocchetta and },
doi = {10.1093/braincomms/fcaf420},
issn = {2632-1297},
year = {2025},
date = {2025-01-01},
journal = {Brain Commun},
volume = {7},
number = {6},
pages = {fcaf420},
abstract = {Thalamic subregions are commonly, but variably, affected by different forms of frontotemporal dementia. We aimed to better characterize thalamic subregional involvement in genetic frontotemporal dementia with a recently published thalamus segmentation tool that utilizes structural and diffusion MRI, offering additional assessment of mean diffusivity and a more fine-grained analysis of the pulvinar specifically compared to previous studies. Using this tool, we performed thalamus segmentations in MRI scans from , and mutation carriers and mutation non-carriers with suitable 3-Tesla MRI cross-sectional data from the GENetic Frontotemporal dementia Initiative. Mutation carriers were divided according to their genetic group and Clinical Dementia Rating® Dementia Staging Instrument plus National Alzheimer's Coordinating Center Behaviour and Language Domains global score (0 or 0.5: presymptomatic/prodromal stage, 1 or higher: symptomatic stage). Following stringent quality control and harmonization across sites and scanners, we compared volumes and mean diffusivity values of thalamic subregions in (47 presymptomatic, 10 symptomatic), (57 presymptomatic, 11 symptomatic) and (31 presymptomatic, 12 symptomatic) mutation carriers to those in 109 mutation non-carriers with analyses of covariance including age and sex (and total intracranial volume for volumetric comparisons) as covariates. Presymptomatic expansion carriers showed smaller volumes (3-8% difference from non-carriers) and higher mean diffusivity (2-5% difference from non-carriers) for several thalamic subregions, including all pulvinar subdivisions. We found subtly larger volumes of the ventral anterior subregion and the non-medial pulvinar (3% difference from non-carriers for both) in presymptomatic mutation carriers, and of the anteroventral subregion (5% difference from non-carriers) in presymptomatic mutation carriers. Symptomatic mutation carriers in all three genetic groups showed significantly smaller volumes and widespread higher mean diffusivity of thalamic subregions compared with non-carriers, which were overall most prominent in subregions involved in associative and limbic functions (the midline, medial pulvinar, anteroventral, mediodorsal, laterodorsal and lateral posterior subregions). Notably smaller volume (12-23% difference from non-carriers) and higher mean diffusivity (16-23% difference from non-carriers) of the most medial part of the medial pulvinar was a shared feature across the three genetic groups at the symptomatic stage. Overall, our study confirms that thalamic subregions are affected in genetic frontotemporal dementia and identifies prominent involvement of the most medial part of the medial pulvinar as a potential unifying feature in the variable pattern of thalamic subregional involvement across the main genetic groups.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Metz, Amelie; Zeighami, Yashar; Ducharme, Simon; Villeneuve, Sylvia; Dadar, Mahsa
Frontotemporal dementia subtyping using machine learning, multivariate statistics and neuroimaging Article de journal
Dans: Brain Commun, vol. 7, no 1, p. fcaf065, 2025, ISSN: 2632-1297.
@article{pmid39990273,
title = {Frontotemporal dementia subtyping using machine learning, multivariate statistics and neuroimaging},
author = {Amelie Metz and Yashar Zeighami and Simon Ducharme and Sylvia Villeneuve and Mahsa Dadar},
doi = {10.1093/braincomms/fcaf065},
issn = {2632-1297},
year = {2025},
date = {2025-01-01},
journal = {Brain Commun},
volume = {7},
number = {1},
pages = {fcaf065},
abstract = {Frontotemporal dementia (FTD) is a prevalent form of early-onset dementia characterized by progressive neurodegeneration and encompasses a group of heterogeneous disorders. Due to overlapping symptoms, diagnosis of FTD and its subtypes still poses a challenge. Magnetic resonance imaging (MRI) is commonly used to support the diagnosis of FTD. Using machine learning and multivariate statistics, we tested whether brain atrophy patterns are associated with severity of cognitive impairment, whether this relationship differs between the phenotypic subtypes and whether we could use these brain patterns to classify patients according to their FTD variant. A total of 136 patients (70 behavioural variant FTD, 36 semantic variant primary progressive aphasia and 30 non-fluent variant primary progressive aphasia) from the frontotemporal lobar degeneration neuroimaging initiative (FTLDNI) database underwent brain MRI and clinical and neuropsychological examination. Deformation-based morphometry, which offers increased sensitivity to subtle local differences in structural image contrasts, was used to estimate regional cortical and subcortical atrophy. Atlas-based associations between atrophy values and performance across different cognitive tests were assessed using partial least squares. We then applied linear regression models to discern the group differences regarding the relationship between atrophy and cognitive decline in the three FTD phenotypes. Lastly, we assessed whether the combination of atrophy and cognition patterns in the latent variables identified in the partial least squares analysis could be used as features in a machine learning model to predict FTD subtypes in patients. Results revealed four significant latent variables that combined accounted for 86% of the shared covariance between cognitive and brain atrophy measures. Partial least squares-based atrophy and cognitive patterns predicted the FTD phenotypes with a cross-validated accuracy of 89.12%, with high specificity (91.46-97.15%) and sensitivity (84.19-93.56%). When using only MRI measures and two behavioural tests in the partial least squares and classification algorithms, ensuring clinical feasibility, our model was equally precise in the same participant sample (87.18%, specificity 76.14-92.00%, sensitivity 86.93-98.26%). Here, including only atrophy or behaviour patterns in the analysis led to prediction accuracies of 69.76% and 76.54%, respectively, highlighting the increased value of combining MRI and clinical measures in subtype classification. We demonstrate that the combination of brain atrophy and clinical characteristics and multivariate statistical methods can serve as a biomarker for disease phenotyping in FTD, whereby the inclusion of deformation-based morphometry measures adds to the classification accuracy in the absence of extensive clinical testing.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
de Boer, Sterre Catharina Maria; Fenoglio, Chiara; Arighi, Andrea; Wissink, Lisa; Riedl, Lina; Rue, Ishana; Landin-Romero, Ramon; Matis, Sophie; Chatterton, Zac; Halliday, Glenda M; Diehl-Schmid, Janine; Piguet, Olivier; Verberk, Inge M W; Teunissen, Charlotte E; Ducharme, Simon; van der Lee, Sven J; Pijnenburg, Yolande A L; Galimberti, Daniela
Dans: BMJ Neurol Open, vol. 7, no 1, p. e001007, 2025, ISSN: 2632-6140.
@article{pmid40486666,
title = {Serum neurofilament light is superior to glial fibrillary acidic protein to distinguish sporadic frontotemporal dementia from late-onset primary psychiatric disorders: a retrospective DIPPA-FTD study},
author = {Sterre Catharina Maria de Boer and Chiara Fenoglio and Andrea Arighi and Lisa Wissink and Lina Riedl and Ishana Rue and Ramon Landin-Romero and Sophie Matis and Zac Chatterton and Glenda M Halliday and Janine Diehl-Schmid and Olivier Piguet and Inge M W Verberk and Charlotte E Teunissen and Simon Ducharme and Sven J van der Lee and Yolande A L Pijnenburg and Daniela Galimberti},
doi = {10.1136/bmjno-2024-001007},
issn = {2632-6140},
year = {2025},
date = {2025-01-01},
journal = {BMJ Neurol Open},
volume = {7},
number = {1},
pages = {e001007},
abstract = {BACKGROUND: Sporadic behavioural variant frontotemporal dementia (bvFTD) is often misdiagnosed as late-onset primary psychiatric disorder (PPD). Previous research in small sample sizes has shown that neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) are promising biomarkers to distinguish FTD from PPD. We aimed to investigate the discriminative value of NfL and GFAP in a multicentre cohort of sporadic bvFTD and late-onset PPD.nnMETHODS: In total, n=275 sporadic bvFTD and n=82 PPD were included from our DIPPA-FTD study. Baseline serum NfL and GFAP levels were measured using Simoa. Biomarker levels were compared between groups. The effect of age and sex on NfL and GFAP was measured using linear regression models. Discriminative accuracies were assessed using logistic regression models and receiver operating characteristic curves, corrected for age and sex. Within a subset of bvFTD patients who were deceased, the prognostic value of biomarkers was assessed by correlating disease duration (age at death minus age at blood sampling) with biomarker levels.nnRESULTS: Significantly higher serum median NfL and GFAP levels were found in sporadic bvFTD (NfL 33.3 pg/mL, IQR (19.6-49.6); GFAP 124.5 pg/mL, IQR (83.5-181.6)) compared with PPD (NfL 12.2 pg/mL, IQR (9.8-17.9); GFAP 68.9 pg/mL, IQR (50.6-95.0), both p<0.001). Discriminative performance was AUC=0.872 for NfL, AUC=0.787 for GFAP and AUC=0.878 for NfL+GFAP (DeLong's p for NfL+GFAP versus NfL AUCs: p=0.286). A shorter disease duration was significantly correlated with higher NfL, but not GFAP.nnCONCLUSION: Our study found that serum GFAP does not provide additional value as a discriminative marker compared with serum NfL alone when differentiating sporadic bvFTD from late-onset PPD.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
de Boer, Sterre C M; Riedl, Lina; Braak, Simon; Fenoglio, Chiara; Foxe, David; Carrick, James; Landin-Romero, Ramón; Matis, Sophie; Chatterton, Zac; Rue, Ishana; van Engelen, Marie-Paule E; Fieldhouse, Jay L P; Oudega, Mardien; Schouws, Sigfried N T M; Krudop, Welmoed A; van Harten, Argonde C; Duits, Flora H; van der Lee, Sven J; Galimberti, Daniela; Diehl-Schmid, Janine; Halliday, Glenda M; Ducharme, Simon; Pijnenburg, Yolande A L; Piguet, Olivier
Differentiating sporadic frontotemporal dementia from late-onset primary psychiatric disorders Article de journal
Dans: Brain Commun, vol. 7, no 3, p. fcaf199, 2025, ISSN: 2632-1297.
@article{pmid40488179,
title = {Differentiating sporadic frontotemporal dementia from late-onset primary psychiatric disorders},
author = {Sterre C M de Boer and Lina Riedl and Simon Braak and Chiara Fenoglio and David Foxe and James Carrick and Ramón Landin-Romero and Sophie Matis and Zac Chatterton and Ishana Rue and Marie-Paule E van Engelen and Jay L P Fieldhouse and Mardien Oudega and Sigfried N T M Schouws and Welmoed A Krudop and Argonde C van Harten and Flora H Duits and Sven J van der Lee and Daniela Galimberti and Janine Diehl-Schmid and Glenda M Halliday and Simon Ducharme and Yolande A L Pijnenburg and Olivier Piguet},
doi = {10.1093/braincomms/fcaf199},
issn = {2632-1297},
year = {2025},
date = {2025-01-01},
journal = {Brain Commun},
volume = {7},
number = {3},
pages = {fcaf199},
abstract = {Sporadic behavioural variant frontotemporal dementia (bvFTD) is often misdiagnosed as late-onset primary psychiatric disorder (PPD) due to overlapping symptoms and lack of biomarkers. We aimed to identify clinical features that distinguish sporadic bvFTD from PPD. Multi-centre baseline data were retrospectively retrieved and categorized into neuropsychological domains. Logistic regression models and receiver operating characteristic curves were conducted to determine discriminators. Data from 508 sporadic bvFTD and 152 PPD cases were included. Higher scores in cognitive screening [odds ratio (OR): 1.23], facial emotion processing (OR: 1.69), episodic memory (OR: 1.09), animal fluency (OR: 1.17), working memory (OR: 1.18), letter fluency (OR: 1.17) and depressive symptoms (OR: 7.41) were significantly associated with PPD (all s ≤ 0.010). Within a combined model, higher scores of letter fluency (OR: 1.47), cognitive screening (OR: 1.72) and lower attention (OR: 0.77) were significantly (all s ≤ 0.05) associated with PPD (area under the curve = 0.771). Neuropsychological measurements-letter fluency, cognitive screening and attention-can help distinguish sporadic bvFTD from late-onset PPD. Depressive symptoms and facial emotion processing emerged as potential discriminators, warranting further exploration.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Andrews, Daniel; Ducharme, Simon; Chertkow, Howard; Sormani, Maria Pia; and, D Louis Collins
The higher benefit of lecanemab in males compared to females in CLARITY AD is probably due to a real sex effect Article de journal
Dans: Alzheimers Dement, vol. 21, no 1, p. e14467, 2025, ISSN: 1552-5279.
@article{pmid39887549,
title = {The higher benefit of lecanemab in males compared to females in CLARITY AD is probably due to a real sex effect},
author = {Daniel Andrews and Simon Ducharme and Howard Chertkow and Maria Pia Sormani and D Louis Collins and },
doi = {10.1002/alz.14467},
issn = {1552-5279},
year = {2025},
date = {2025-01-01},
journal = {Alzheimers Dement},
volume = {21},
number = {1},
pages = {e14467},
abstract = {INTRODUCTION: The phase 3 trial CLARITY AD found lecanemab slowed cognitive decline by 27%. However, subgroup analyses indicated a significant 31% sex difference in the effect and suggested no or limited effectiveness in females. We used simulations constrained by the trial design to determine whether that difference reflects a pre-existing sex difference in Alzheimer's disease progression or was a random event.nnMETHODS: Simulations were generated using linear mixed models of cognitive decline fit to data from Alzheimer's Disease Neuroimaging Initiative participants satisfying CLARITY AD inclusion criteria.nnRESULTS: The statistically non-significant 7.9% smaller cognitive decline rate in our cohort's males versus females does not explain CLARITY AD's 31% sex difference in lecanemab's effect. A ≥ 31% difference occurred randomly in only 12 of our 10,000 simulations (0.0012 probability).nnDISCUSSION: CLARITY AD's sex difference was probably not random. Lecanemab is likely less effective in females than males, but we cannot conclude the drug is ineffective in females.nnHIGHLIGHTS: Lecanemab is more clinically effective in males than in females. Forest plots should only report subgroup-specific effects in well-powered subgroups. Trial simulations based on real data enable investigation of subgroup drug effects. We cannot conclude that lecanemab is clinically ineffective in females. A sex difference in lecanemab's efficacy could be linked to its action mechanism.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
van Paassen, Dirk; Hartog, Luc; de Boer, Sterre; Vijverberg, Everard; Ducharme, Simon; Pijnenburg, Yolande; Santillo, Alexander
Dans: Eur J Neurol, vol. 32, no 1, p. e16537, 2025, ISSN: 1468-1331.
@article{pmid39607834,
title = {Expert opinions on pharmacological symptomatic treatment of behavioral symptoms in frontotemporal dementia: A survey of the Neuropsychiatric International Consortium on Frontotemporal Dementia (NIC-FTD)},
author = {Dirk van Paassen and Luc Hartog and Sterre de Boer and Everard Vijverberg and Simon Ducharme and Yolande Pijnenburg and Alexander Santillo},
doi = {10.1111/ene.16537},
issn = {1468-1331},
year = {2025},
date = {2025-01-01},
journal = {Eur J Neurol},
volume = {32},
number = {1},
pages = {e16537},
abstract = {BACKGROUND AND PURPOSE: Behavioral variant frontotemporal dementia (bvFTD) is essentially characterized by progressive changes in personality and cognition. Clinically, bvFTD presents with often profound behavioral symptomatology. Despite the high burden of these symptoms for both patients and caregivers, there is no general consensus on an effective pharmacological symptomatic treatment. Interestingly, for multiple similar symptoms in primary psychiatric disorders, there is consensus on an effective pharmacological treatment. The aim of this study is to explore currently preferred clinical practices in the pharmacological treatment of specific core behavioral symptoms in bvFTD by world-leading clinical experts.nnMETHODS: A digital survey was conducted among members of the Neuropsychiatric International Consortium on Frontotemporal Dementia, comprising neurologists, psychiatrists, and neuropsychiatrists. Respondents recommended pharmacological treatments targeting symptoms including disinhibition, apathy, loss of empathy, hyperorality, perseverative/compulsive behaviors, and positive psychotic symptoms.nnRESULTS: Of 48 respondents with a median experience of 11.5 years in treating bvFTD, disinhibition was most frequently targeted (58.4%), followed by perseverative/compulsive behaviors (46.5%). Recommended drug classes included atypical antipsychotics (35.1%), selective serotonin reuptake inhibitors (31.2%), antiepileptics (10.0%), serotonin antagonist and reuptake inhibitors (8.4%), benzodiazepines (4.0%), and others (11.4%).nnCONCLUSIONS: Our survey revealed diverse pharmacological treatment practices for behavioral symptoms in bvFTD, reflecting the expected radical heterogeneity in pharmacological treatment strategies. Notwithstanding this, results from this explorative survey could further inform future research directions, and thus in turn potentially aid in establishing more consensus on effective pharmacological management of bvFTD, while the field awaits the development of highly anticipated disease-modifying treatment(s).},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
2024
Chertkow, Howard; Phillips, Natalie; Rockwood, Kenneth; Anderson, Nicole; Andrew, Melissa K; Bartha, Robert; Beaudoin, Camille; Bélanger, Nathalie; Bellec, Pierre; Belleville, Sylvie; Bergman, Howard; Best, Sarah; Bethell, Jennifer; Bherer, Louis; Black, Sandra; Borrie, Michael; Camicioli, Richard; Carrier, Julie; Cashman, Neil; Chan, Senny; Crowshoe, Lynden; Cuello, Claudio; Cynader, Max; Dang-Vu, Thanh; Das, Samir; Dixon, Roger A; Ducharme, Simon; Einstein, Gillian; Evans, Alan C; Fahnestock, Margaret; Feldman, Howard; Ferland, Guylaine; Finger, Elizabeth; Fisk, John D; Fogarty, Jennifer; Fon, Edward; Gan-Or, Ziv; Gauthier, Serge; Greenwood, Carol; Henri-Bellemare, Charlie; Herrmann, Nathan; Hogan, David B; Hsiung, Robin; Itzhak, Inbal; Jacklin, Kristen; Lanctôt, Krista; Lim, Andrew; MacKenzie, Ian; Masellis, Mario; Maxwell, Colleen; McAiney, Carrie; McGilton, Katherine; McLaurin, JoAnne; Mihailidis, Alex; Mohades, Zia; Montero-Odasso, Manuel; Morgan, Debra; Naglie, Gary; Nygaard, Haakon; O'Connell, Megan; Petersen, Ron; Pilon, Randi; Rajah, Maria Natasha; Rapoport, Mark; Roach, Pamela; Robillard, Julie M; Rogaeva, Ekaterina; Rosa-Neto, Pedro; Rylett, Jane; Sadavoy, Joel; George-Hyslop, Peter St; Seitz, Dallas; Smith, Eric; Stefanovic, Bojana; Vedel, Isabelle; Walker, Jennifer D; Wellington, Cheryl; Whitehead, Victor; Wittich, Walter
Impact of a national dementia research consortium: The Canadian Consortium on Neurodegeneration in Aging (CCNA) Article de journal
Dans: J Alzheimers Dis, vol. 102, no 3, p. 535–561, 2024, ISSN: 1875-8908.
@article{pmid39636028,
title = {Impact of a national dementia research consortium: The Canadian Consortium on Neurodegeneration in Aging (CCNA)},
author = {Howard Chertkow and Natalie Phillips and Kenneth Rockwood and Nicole Anderson and Melissa K Andrew and Robert Bartha and Camille Beaudoin and Nathalie Bélanger and Pierre Bellec and Sylvie Belleville and Howard Bergman and Sarah Best and Jennifer Bethell and Louis Bherer and Sandra Black and Michael Borrie and Richard Camicioli and Julie Carrier and Neil Cashman and Senny Chan and Lynden Crowshoe and Claudio Cuello and Max Cynader and Thanh Dang-Vu and Samir Das and Roger A Dixon and Simon Ducharme and Gillian Einstein and Alan C Evans and Margaret Fahnestock and Howard Feldman and Guylaine Ferland and Elizabeth Finger and John D Fisk and Jennifer Fogarty and Edward Fon and Ziv Gan-Or and Serge Gauthier and Carol Greenwood and Charlie Henri-Bellemare and Nathan Herrmann and David B Hogan and Robin Hsiung and Inbal Itzhak and Kristen Jacklin and Krista Lanctôt and Andrew Lim and Ian MacKenzie and Mario Masellis and Colleen Maxwell and Carrie McAiney and Katherine McGilton and JoAnne McLaurin and Alex Mihailidis and Zia Mohades and Manuel Montero-Odasso and Debra Morgan and Gary Naglie and Haakon Nygaard and Megan O'Connell and Ron Petersen and Randi Pilon and Maria Natasha Rajah and Mark Rapoport and Pamela Roach and Julie M Robillard and Ekaterina Rogaeva and Pedro Rosa-Neto and Jane Rylett and Joel Sadavoy and Peter St George-Hyslop and Dallas Seitz and Eric Smith and Bojana Stefanovic and Isabelle Vedel and Jennifer D Walker and Cheryl Wellington and Victor Whitehead and Walter Wittich},
doi = {10.1177/13872877241290990},
issn = {1875-8908},
year = {2024},
date = {2024-12-01},
journal = {J Alzheimers Dis},
volume = {102},
number = {3},
pages = {535--561},
abstract = {The Canadian Consortium on Neurodegeneration in Aging (CCNA) was created by the Canadian federal government through its health research funding agency, the Canadian Institutes for Health Research (CIHR), in 2014, as a response to the G7 initiative to fight dementia. Two five-year funding cycles (2014-2019; 2019-2024) have occurred following peer review, and a third cycle (Phase 3) has just begun. A unique construct was mandated, consisting of 20 national teams in Phase I and 19 teams in Phase II (with research topics spanning from basic to clinical science to health resource systems) along with cross-cutting programs to support them. Responding to the needs of researchers within the CCNA teams, a unique sample of 1173 deeply phenotyped patients with various forms of dementia was accrued and studied over eight years (COMPASS-ND). In the second phase of funding (2019-2024), a national dementia prevention program (CAN-THUMBS UP) was set up. In a short time, this prevention program became a member of the World Wide FINGERS prevention consortium. In this article, the challenges, successes, and impacts of CCNA in Canada and internationally are discussed. Short-term deliverables have occurred, along with considerable promise of impacts in the longer term. The creation of synergy, networking, capacity building, engagement of people with lived experience, and economies of scale have contributed to the considerable success of CCNA by all measures. CCNA is evidence that an organized "centrally-organized" approach to dementia research can catalyze important progress nationally and yield significant and measurable results.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Fenoglio, Chiara; Serpente, Maria; Arcaro, Marina; Carandini, Tiziana; Sacchi, Luca; Pintus, Manuela; Rotondo, Emanuela; Borracci, Vittoria; Ghezzi, Laura; Bouzigues, Arabella; Russell, Lucy L; Foster, Phoebe H; Ferry-Bolder, Eve; van Swieten, John C; Jiskoot, Lize C; Seelaar, Harro; Valle, Raquel Sánchez; Laforce, Robert; Graff, Caroline; Vandenberghe, Rik; de Mendonça, Alexandre; Tiraboschi, Pietro; Santana, Isabel; Gerhard, Alexander; Levin, Johannes; Sorbi, Sandro; Otto, Markus; Pasquier, Florence; Ducharme, Simon; Butler, Chris R; Ber, Isabelle Le; Finger, Elizabeth; Tartaglia, Maria Carmela; Masellis, Mario; Rowe, James B; Synofzik, Matthis; Moreno, Fermin; Borroni, Barbara; Rohrer, Jonathan D; Arighi, Andrea; and, Daniela Galimberti
Inflammatory plasma profile in genetic symptomatic and presymptomatic Frontotemporal Dementia - A GENFI study Article de journal
Dans: Brain Behav Immun, vol. 122, p. 231–240, 2024, ISSN: 1090-2139.
@article{pmid39153518,
title = {Inflammatory plasma profile in genetic symptomatic and presymptomatic Frontotemporal Dementia - A GENFI study},
author = {Chiara Fenoglio and Maria Serpente and Marina Arcaro and Tiziana Carandini and Luca Sacchi and Manuela Pintus and Emanuela Rotondo and Vittoria Borracci and Laura Ghezzi and Arabella Bouzigues and Lucy L Russell and Phoebe H Foster and Eve Ferry-Bolder and John C van Swieten and Lize C Jiskoot and Harro Seelaar and Raquel Sánchez Valle and Robert Laforce and Caroline Graff and Rik Vandenberghe and Alexandre de Mendonça and Pietro Tiraboschi and Isabel Santana and Alexander Gerhard and Johannes Levin and Sandro Sorbi and Markus Otto and Florence Pasquier and Simon Ducharme and Chris R Butler and Isabelle Le Ber and Elizabeth Finger and Maria Carmela Tartaglia and Mario Masellis and James B Rowe and Matthis Synofzik and Fermin Moreno and Barbara Borroni and Jonathan D Rohrer and Andrea Arighi and Daniela Galimberti and },
doi = {10.1016/j.bbi.2024.08.030},
issn = {1090-2139},
year = {2024},
date = {2024-11-01},
journal = {Brain Behav Immun},
volume = {122},
pages = {231--240},
abstract = {BACKGROUND: Inflammation has been proposed as a crucial player in neurodegeneration, including Frontotemporal Dementia (FTD). A few studies on sporadic FTD lead to inconclusive results, whereas large studies on genetic FTD are lacking. The aim of this study is to determine cytokine and chemokine plasma circulating levels in a large cohort of genetic FTD, collected within the GENetic Frontotemporal dementia Initiative (GENFI).nnMETHODS: Mesoscale technology was used to analyse levels of 30 inflammatory factors in 434 plasma samples, including 94 Symptomatic Mutation carriers [(SMC); 15 with mutations in Microtubule Associated Protein Tau (MAPT) 34 in Progranulin (GRN) and 45 in Chromosome 9 Open Reading Frame (C9ORF)72], 168 Presymptomatic Mutation Carriers (PMC; 34 MAPT, 70 GRN and 64 C9ORF72) and 173 Non-carrier Controls (NC)].nnRESULTS: The following cytokines were significantly upregulated (P<0.05) in MAPT and GRN SMC versus NC: Tumor Necrosis Factor (TNF)α, Interleukin (IL)-7, IL-15, IL-16, IL-17A. Moreover, only in GRN SMC, additional factors were upregulated, including: IL-1β, IL-6, IL-10, IL-12/IL-23p40, eotaxin, eotaxin-3, Interferon γ-induced Protein (IP-10), Monocyte Chemotactic Protein (MCP)4. On the contrary, IL-1α levels were decreased in SMC compared with NC. Significantly decreased levels of this cytokine were also found in PMC, independent of the type of mutation. In SMC, no correlations between disease duration and cytokine and chemokine levels were found. Considering NfL and GFAP levels, as expected, significant increases were observed in SMC as compared to NC. These differences in mean values remain significant even when stratifying symptomatic patients by the mutated gene (P<0.0001). Considering instead the levels of NfL, GFAP, and the altered inflammatory molecules, no significant correlations emerged.nnCONCLUSION: We showed that inflammatory proteins are upregulated in MAPT and GRN SMC, with some specific factors altered in GRN only, whereas no changes were seen in C9ORF72 carriers. Notably, only IL-1α levels were decreased in both SMC and PMC, independent of the type of causal mutation, suggesting common modifications occurring in the preclinical phase of the disease.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Weinhold, Erin R; Vaughan, Christina L; O'Hara, Mary; Bloemen, Elizabeth M; Bakeman, Delia; Ducharme, Simon; Pressman, Peter S
Clinical considerations regarding suspected "BvFTD-by-proxy": a case series Article de journal
Dans: Neurocase, vol. 30, no 4, p. 135–141, 2024, ISSN: 1465-3656.
@article{pmid39462825,
title = {Clinical considerations regarding suspected "BvFTD-by-proxy": a case series},
author = {Erin R Weinhold and Christina L Vaughan and Mary O'Hara and Elizabeth M Bloemen and Delia Bakeman and Simon Ducharme and Peter S Pressman},
doi = {10.1080/13554794.2024.2419177},
issn = {1465-3656},
year = {2024},
date = {2024-08-01},
journal = {Neurocase},
volume = {30},
number = {4},
pages = {135--141},
abstract = {A diagnosis of behavioral variant frontotemporal dementia (bvFTD) often relies on informant reports of significant behavioral changes. "BvFTD-by-proxy" describes situations of neuropsychiatric changes reported solely by an informant under circumstances that may raise questions regarding their objectivity. We present three cases of bvFTD-like symptoms reported by spouses, where progression was unclear, testing showed mild but stable executive dysfunction, and neuroimaging was unremarkable. The subjective nature of bvFTD criteria leaves patients vulnerable to misleading informant reports, especially amid relational discord, and may threaten patient autonomy. Recognizing and managing this situation is critical but time-consuming, often requiring coordinated care across multiple providers.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Ulugut, Hulya; Bertoux, Maxime; Younes, Kyan; Montembeault, Maxime; Fumagalli, Giorgio G; Samanci, Bedia; Illán-Gala, Ignacio; Kuchcinski, Gregory; Leroy, Melanie; Thompson, Jennifer C; Kobylecki, Christopher; Santillo, Alexander F; Englund, Elisabet; Waldö, Maria Landqvist; Riedl, Lina; den Stock, Jan Van; Vandenbulcke, Mathieu; Vandenberghe, Rik; Laforce, Robert; Ducharme, Simon; Pressman, Peter S; Caramelli, Paulo; de Souza, Leonardo Cruz; Takada, Leonel T; Gurvit, Hakan; Hansson, Oskar; Diehl-Schmid, Janine; Galimberti, Daniela; Pasquier, Florence; Miller, Bruce L; Scheltens, Philip; Ossenkoppele, Rik; van der Flier, Wiesje M; Barkhof, Frederik; Fox, Nick C; Sturm, Virginia E; Miyagawa, Toji; Whitwell, Jennifer L; Boeve, Bradley; Rohrer, Jonathan D; Gorno-Tempini, Maria Luisa; Josephs, Keith A; Snowden, Julie; Warren, Jason D; Rankin, Katherine P; and, Yolande A L Pijnenburg
Clinical recognition of frontotemporal dementia with right anterior temporal predominance: A multicenter retrospective cohort study Article de journal
Dans: Alzheimers Dement, vol. 20, no 8, p. 5647–5661, 2024, ISSN: 1552-5279.
@article{pmid38982845,
title = {Clinical recognition of frontotemporal dementia with right anterior temporal predominance: A multicenter retrospective cohort study},
author = {Hulya Ulugut and Maxime Bertoux and Kyan Younes and Maxime Montembeault and Giorgio G Fumagalli and Bedia Samanci and Ignacio Illán-Gala and Gregory Kuchcinski and Melanie Leroy and Jennifer C Thompson and Christopher Kobylecki and Alexander F Santillo and Elisabet Englund and Maria Landqvist Waldö and Lina Riedl and Jan Van den Stock and Mathieu Vandenbulcke and Rik Vandenberghe and Robert Laforce and Simon Ducharme and Peter S Pressman and Paulo Caramelli and Leonardo Cruz de Souza and Leonel T Takada and Hakan Gurvit and Oskar Hansson and Janine Diehl-Schmid and Daniela Galimberti and Florence Pasquier and Bruce L Miller and Philip Scheltens and Rik Ossenkoppele and Wiesje M van der Flier and Frederik Barkhof and Nick C Fox and Virginia E Sturm and Toji Miyagawa and Jennifer L Whitwell and Bradley Boeve and Jonathan D Rohrer and Maria Luisa Gorno-Tempini and Keith A Josephs and Julie Snowden and Jason D Warren and Katherine P Rankin and Yolande A L Pijnenburg and },
doi = {10.1002/alz.14076},
issn = {1552-5279},
year = {2024},
date = {2024-08-01},
journal = {Alzheimers Dement},
volume = {20},
number = {8},
pages = {5647--5661},
abstract = {INTRODUCTION: Although frontotemporal dementia (FTD) with right anterior temporal lobe (RATL) predominance has been recognized, a uniform description of the syndrome is still missing. This multicenter study aims to establish a cohesive clinical phenotype.nnMETHODS: Retrospective clinical data from 18 centers across 12 countries yielded 360 FTD patients with predominant RATL atrophy through initial neuroimaging assessments.nnRESULTS: Common symptoms included mental rigidity/preoccupations (78%), disinhibition/socially inappropriate behavior (74%), naming/word-finding difficulties (70%), memory deficits (67%), apathy (65%), loss of empathy (65%), and face-recognition deficits (60%). Real-life examples unveiled impairments regarding landmarks, smells, sounds, tastes, and bodily sensations (74%). Cognitive test scores indicated deficits in emotion, people, social interactions, and visual semantics however, lacked objective assessments for mental rigidity and preoccupations.nnDISCUSSION: This study cumulates the largest RATL cohort unveiling unique RATL symptoms subdued in prior diagnostic guidelines. Our novel approach, combining real-life examples with cognitive tests, offers clinicians a comprehensive toolkit for managing these patients.nnHIGHLIGHTS: This project is the first international collaboration and largest reported cohort. Further efforts are warranted for precise nomenclature reflecting neural mechanisms. Our results will serve as a clinical guideline for early and accurate diagnoses.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Nouvelles
Un médicament pourrait retarder de plusieurs années l’alzheimer – Dr. Ducharme
13 octobre 2026, Un médicament à l’étude pour retarder l’apparition de la maladie d’Alzheimer Dans un article publié par TVA Nouvelles, le Dr Simon Ducharme présente une recherche clinique internationale visant à retarder l’apparition des symptômes de la maladie d’Alzheimer. Cette étude évalue une approche thérapeutique ciblant la protéine amyloïde avant l’apparition des symptômes, auprès…
Les Drs El Mestikawy et Ducharme financés par le CQDM pour deux projets collaboratifs
le 18 juin 2026 Nous sommes heureux d’annoncer que le CQDM finance deux projets menés par des chercheurs du Douglas, les Drs Simon Ducharme et Salah El Mestikawy. Leurs projets figurent parmi six projets collaboratifs de R&D soutenus par le CQDM et qui représentent collectivement un investissement total de 10 173 321 $. Appuyées par…
Le Dr Simon Ducharme mis en vedette dans Découverte
Le Dr. Simon Ducharme apparaît dans le récent épisode du documentaire Découverte, diffusé sur Radio-Canada. Alzheimer : l’arrivée de molécules innovantesDe nouvelles molécules pour freiner la maladie d’Alzheimer arrivent sur le marché. Un espoir qui, après analyse, cède le pas à la déception. Nos systèmes de santé ne sont peut-être pas prêts à supporter la…
Des candidats du Douglas reçoivent des bourses de recherche postdoctorale des IRSC
Le 8 avril 2026 Nous avons le plaisir de vous présenter la liste des stagiaires du Centre de recherche Douglas qui ont obtenu une bourse de recherche postdoctorale des IRSC. Le programme des bourses de recherche postdoctorale du Canada (BRPC) vise à reconnaître et à soutenir la prochaine génération d’innovateurs, de travailleurs du savoir, de…
L’IA en santé mentale, entre risques et innovation – Dr Ducharme
Dans un article publié sur Radio-Canada Info, le Dr Simon Ducharme aborde le rôle croissant de l’intelligence artificielle en santé mentale et en recherche psychiatrique. L’article explore à la fois les risques et le potentiel des agents conversationnels en santé mentale, ainsi que les innovations rendues possibles par l’IA. Le Dr Ducharme y présente notamment…
Un biomarqueur sanguin prometteur pour distinguer démence et troubles psychiatriques
Le 7 décembre 2025 — Récit d’impact des FRQS Les travaux menés par le Dr Simon Ducharme a fait l’objet d’un récit d’impact sur le site des Fonds de recherche du Québec (FRQS), soulignant la portée clinique et sociétale de ces études. Le Dr Ducharme et son équipe travaillent à améliorer la distinction entre les…
Un médicament pour ralentir la maladie d’Alzheimer autorisé par Santé Canada – Dr Ducharme
Santé Canada vient d’approuver le lécanémab, un médicament déjà autorisé dans plusieurs autres pays pour le traitement de la maladie d’Alzheimer. Ce traitement pourrait retarder l’apparition des symptômes d’environ un an chez les personnes à risque. Dans un reportage publié dans Le Téléjournal (Radio-Canada), Dr Ducharme partage son son expertise sur ce nouveau traitement et…
Lutte contre la maladie d’Alzheimer : Guerre scientifique autour de nouveaux médicaments – Dr Simon Ducharme
Le Dr. Simon Ducharme a pris part à un entretien publié dans La Presse sur les nouveaux médicaments contre la maladie d’Alzheimer, dont le lécanémab.Cet article présente un débat entre spécialistes quant aux bénéfices et aux risques de ces traitements émergents. “Les données à long terme sont enthousiasmantes : en quatre ans, on a allongé d’un…
Prendre soin d’une personne atteinte d’un trouble neurocognitif : ce qu’il faut savoir sur les hallucinations, les troubles délirants et la paranoïa – Dr Simon Ducharme
Dans cet épisode de McGill Cares, une série de webdiffusions pour soutenir les aidants naturels, le Dr Simon Ducharme explique comment la démence peut entraîner hallucinations, délires et paranoïa. Il détaille leur impact sur la personne atteinte et ses proches, et propose des stratégies pratiques pour mieux gérer ces situations, ainsi que des conseils pour…
Annonce des lauréats des prix étudiants de la Journée de la recherche 2025
Le Centre de recherche Douglas et le Département de psychiatrie de l’Université McGill ont tenu leur Journée de la recherche annuelle le jeudi 19 juin 2025. Comme chaque année, la participation et la contribution de nombreux stagiaires, chercheurs et bénévoles ont permis d’assurer le succès de cet événement! De nombreuses présentations orales courtes et longues…







